
Keith Bricker 🇺🇸
620 posts

Keith Bricker 🇺🇸
@KeithBricker
Want the best for everyone




$IBRX I couldn't get that Press Release from Friday out of my head. So I asked Grok to explain it to me. I was astonished! The explanation I received from Grok was unbelievable positive!!! So I asked Grok to rewrite the Press Release in a way that people like me could understand it. Hope you enjoy this alternative PR! Boy, I really hope the company will rephrase Friday's press release!! ImmunityBio Reports Encouraging Early Results in Recurrent Glioblastoma: Many Patients Alive Well Beyond Typical Survival CULVER CITY, Calif. – January 23, 2026 – ImmunityBio, Inc. (NASDAQ: IBRX) today shared promising interim Phase 2 data from QUILT-3.078 in recurrent glioblastoma, one of the deadliest brain cancers. Glioblastoma is extremely aggressive: after recurrence following standard treatment (surgery, radiation, temozolomide), most patients survive only 6–9 months. Five-year survival remains under 10%. In this trial, as of January 22, 2026, 23 patients with recurrent Glioblastoma were enrolled — 19 remain alive. Among 14 with sufficient follow-up, survival is exceeding historical norms, including one patient at 12+ months ongoing from progression. The therapy also reversed severe lymphopenia, boosting levels significantly and sustaining gains through 20 weeks. “These durable signals in such a lethal disease offer real hope,” said Patrick Soon-Shiong, M.D., Founder and Executive Chairman. Larger randomized trials are advancing. Updated results will be presented January 31, 2026, at the Stand Up to Cancer Glioblastoma Summit.



@cvpayne @dagenmcdowell Deeper economic perspective from Bill:






























